- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dapagliflozin may improve erectile dysfunction among diabetes patients
![Dapagliflozin may improve erectile dysfunction among diabetes patients Dapagliflozin may improve erectile dysfunction among diabetes patients](https://medicaldialogues.in/h-upload/2020/04/02/750x450_126179-erectile-dysfunction.webp)
Italy: A recent study published in Diabetic Medicine has shown the positive effect of dapagliflozin on erectile function in patients with type 2 diabetes (T2D) and erectile dysfunction. Dapagliflozin is a member of SGLT2 inhibitors, a relatively new class of antidiabetic drugs.
The researchers revealed that patients treated with dapagliflozin plus tadalafil showed the greatest degree of improvement in erectile dysfunction, suggesting the dapagliflozin's ability to enhance the efficacy of tadalafil. This could have important implications for clinical practice.
Improvement in erectile dysfunction with dapagliflozin treatment was demonstrated by the increase in the International Index of Erectile Function 5-item questionnaire scores, and the improvement in the peak systolic velocity and the acceleration time in the cavernous arteries at dynamic penile echo colour Doppler ultrasound observed after treatment.
Erectile dysfunction is defined as the ability to maintain or achieve a rigid penile erection allowing for rewarding intercourse. It widely affects patients with type 2 diabetes mellitus. The role of dapagliflozin on erectile dysfunction has not yet been studied. Considering this, Rossella Cannarella, University of Catania, Catania, Italy, and colleagues aimed to evaluate the effects of dapagliflozin alone or in combination with tadalafil on ED in patients with T2D in an open-label, non-randomized pilot study.
The study included 30 Caucasian male patients with type 2 diabetes and severe erectile dysfunction. They were divided equally into three groups, Group 1; assigned to treatment with 5 mg/day tadalafil, Group 2; tadalafil 5 mg/day plus dapagliflozin 10 mg/day, and Group 3; dapagliflozin 10 mg/day for three months.
The presence and severity of ED were assessed at enrollment and after treatment by the dynamic penile echo colour Doppler ultrasound (PCDU) examination and the International Index of Erectile Function 5-item (IIEF-5) questionnaire.
The study led to the following findings:
- At the end of treatment, the three groups showed a significant improvement in IIEF-5 score, by 294%, 375% and 197%, in Groups 1, 2 and 3, respectively.
- PCDU evaluation showed a significant increase in peak systolic velocity by 178.9%, 339% and 153%; acceleration time was significantly shortened in Group 2 (−26.2%) and was significantly lower than in Group 1 and 3 (−7.2% and −6.6%), while no significant difference was found in end-diastolic velocity after treatment.
- The greatest rates of improvement were observed in Group 2 for all the endpoints.
"Our findings showed that dapagliflozin improves erectile dysfunction in patients with type 2 diabetes and enhances the efficacy of tadalafil," the researchers wrote. "There is a need for further studies to confirm our results and explain the mechanism(s) by which dapagliflozin exerts its effects on erectile dysfunction."
Reference:
Cannarella, R., Condorelli, R. A., Leanza, C., Garofalo, V., Aversa, A., Papa, G., Calogero, A. E., & Vignera, S. L. Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open-label, non-randomized pilot study. Diabetic Medicine, e15217. https://doi.org/10.1111/dme.15217
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751